Clinical Outcomes in COVID-19 and Liver Cirrhosis

Abstract Background Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the ongoing COVID-19 pandemic. While pre-existing conditions contribute to COVID-19 severity, the impact of liver disease on outcomes remains unclear. The global impact of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has prompted investigations into its association with pre- existing conditions. Notably, the influence of liver disease on COVID-19 outcomes remains poorly understood. Aim of the Work to study the clinical outcomes of covid-19 in the cirrhotic patients Patients and Methods We conducted a retrospective analysis of COVID-19 patients with liver disease, liver cirrhosis, and COVID-19 without liver involvement. Demographics, comorbidities, laboratory results, and imaging findings were assessed. Results Significant variations in biochemical markers were observed among the groups. AST, ALT, and bilirubin levels demonstrated distinct patterns in patients with liver cirrhosis compared to those without liver involvement. These findings underscore the need to consider liver function parameters when assessing COVID-19 patients. Liver cirrhosis appears to correlate with worse COVID-19 outcomes. Altered biochemical markers and inflammatory responses in cirrhosis warrant further investigation. This retrospective study underscores the importance of understanding liver disease's implications for COVID-19. Liver cirrhosis patients exhibit unique biochemical profiles that contribute to their outcomes. Conclusion in this retrospective analysis, we shed light on the potential impact of underlying liver disease, particularly cirrhosis, on COVID-19 outcomes. The distinct biochemical profiles observed in patients with liver cirrhosis suggest that liver status may influence disease severity. As the COVID-19 pandemic evolves, understanding these interactions becomes pivotal for tailored patient care.